CRMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CRMD is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some positive fundamental interest from analysts, but the technical picture is still mixed to weak and there is no fresh news catalyst or insider/congress buying support. Since you are impatient and do not want to wait for a perfect entry, this is still not an ideal immediate buy; a hold is the better call until the trend improves above resistance with more confirmation.
Current price is 8.74, essentially flat versus the previous close of 8.75, with a modest regular-session gain of 3.31% intraday context and the broader market slightly negative. The trend remains cautious: MACD histogram is negative at -0.0418, though contracting, which suggests bearish momentum is easing. RSI_6 at 65.788 is neutral-to-strong but not overbought enough to confirm a breakout. The moving-average structure is bearish (SMA_200 > SMA_20 > SMA_5), which means the longer-term trend is still not fully constructive. Key levels: pivot 8.277, resistance 8.875, then 9.244; support 7.679 and 7.31. The stock is trading near first resistance, so upside needs a clean break above 8.875 to improve the setup. The model trend note also suggests only modest upside over time, with a 60% chance of -0.74% next day, then +1.04% next week and +1.93% next month.
RBC Capital raised its price target to $14 from $13 and kept an Outperform rating after positive topline phase 3 results for Rezzayo. The analyst commentary says Rezzayo appears competitive, with broad-spectrum activity, favorable tolerability, and fewer discontinuations. Options positioning is also bullish, with call activity dominating put activity. There is no negative news in the past week.
No recent news catalyst in the last week, so the stock lacks a fresh near-term driver. The technical trend is still bearish on moving averages, and MACD remains below zero. Hedge funds and insiders are both neutral with no significant recent buying trend. There is no congress trading data to support the name. The stock is also sitting near resistance rather than breaking out cleanly.
No usable financial snapshot was provided due to an error, so latest-quarter revenue and earnings growth cannot be assessed here. Because the latest quarter season is unavailable in the data, I cannot confirm the most recent fundamental acceleration or profitability trend from this dataset.
Analyst sentiment is constructive and improving. RBC Capital lifted its price target to $14 from $13 and maintained an Outperform rating on 2026-04-28, following positive phase 3 topline results. Wall Street’s pros view is that the drug profile looks competitive with favorable tolerability and fewer discontinuations. The cons view is that the stock price has not yet confirmed that optimism through a strong technical breakout, and the latest trading trend data remains neutral.
